LBH589, Paclitaxel, Carboplatin +/- Bevacizumab for Solid Tumors
|ClinicalTrials.gov Identifier: NCT00556088|
Recruitment Status : Completed
First Posted : November 9, 2007
Last Update Posted : December 30, 2010
|Condition or disease||Intervention/treatment||Phase|
|Solid Tumors||Drug: LBH589, Paclitaxel, Carboplatin, Bevacizumab||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||40 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase I Study of LBH589 in Combination With Paclitaxel and Carboplatin +/- Bevacizumab the Treatment of Solid Tumors|
|Study Start Date :||December 2007|
|Primary Completion Date :||July 2010|
|Study Completion Date :||July 2010|
Experimental: Part 1
Part I Phase I dose escalation trial. LBH589 will be administered orally on Monday and Thursday or Tuesday and Friday each week (twice weekly). Paclitaxel and carboplatin will be administered intravenously every 21 days.
Part II LBH589, paclitaxel, and carboplatin dosing will be determined in the first phase of this study (Phase I). The drug dosages to be administered will be reduced one level from the determined Maximum Tolerated Dose (MTD). In addition, bevacizumab 15 mg/kg will be added to the second portion of this trial.
Drug: LBH589, Paclitaxel, Carboplatin, Bevacizumab
LBH589 will be administered orally twice weekly. Paclitaxel and carboplatin will be administered intravenously every 21 days.
Once the MTD is established, drug dosages will be adjusted downward by one dose level and bevacizumab 15mg/kg intravenously every 3 weeks will be administered to a subset of patients with non-small cell lung cancer.
- Determine the maximally tolerated doses and dose limiting toxicities of LBH589 in combination with paclitaxel and carboplatin. Preliminary anti-tumor activity will also be assessed. [ Time Frame: 18 months ]
- Determine the tolerability and preliminary efficacy in a subset of patients with non-small cell lung cancer. [ Time Frame: 18 months ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00556088
|United States, Tennessee|
|Tennessee Oncology, PLLC|
|Nashville, Tennessee, United States, 37023|
|Study Chair:||Howard A. Burris, M.D.||SCRI Development Innovations, LLC|